RATIONALE: Long-acting beta-agonists (LABAs) and inhaled corticosteroids administered together appear to be complementary in terms of effects on asthma control. The elements of asthma control achieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection against exacerbations) may be complementary as well. OBJECTIVE: We sought to determine whether the combination of the LTRA montelukast and the LABA salmeterol could provide an effective therapeutic strategy for asthma. METHODS AND MEASUREMENTS: In a randomized, placebo-controlled, crossover study of 192 subjects with moderate asthma, we compared the clinical efficacy of regular treatment over 14 weeks with the combination of montelukast and salmeterol to that with the combination of beclomethasone and salmeterol in moderate asthma. The primary efficacy outcome was time to treatment failure. MAIN RESULTS: Three months after the randomization of the last subject, the Data and Safety Monitoring Board determined that the primary research question had been answered and terminated the trial. The combination of montelukast and salmeterol was inferior to the combination of beclomethasone and salmeterol as judged by protection against asthma treatment failures (p = 0.0008), lung function (26 L/min difference in a.m. peak expiratory flow rate, p = 0.011), asthma control score (0.22 difference in Asthma Control Questionnaire score, p = 0.038), and markers of inflammation and airway reactivity. CONCLUSIONS:Patients with moderate asthma similar to those we studied should not substitute the combination of an LTRA and an LABA for the combination of inhaled corticosteroid and an LABA.
RCT Entities:
RATIONALE: Long-acting beta-agonists (LABAs) and inhaled corticosteroids administered together appear to be complementary in terms of effects on asthma control. The elements of asthma control achieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection against exacerbations) may be complementary as well. OBJECTIVE: We sought to determine whether the combination of the LTRA montelukast and the LABA salmeterol could provide an effective therapeutic strategy for asthma. METHODS AND MEASUREMENTS: In a randomized, placebo-controlled, crossover study of 192 subjects with moderate asthma, we compared the clinical efficacy of regular treatment over 14 weeks with the combination of montelukast and salmeterol to that with the combination of beclomethasone and salmeterol in moderate asthma. The primary efficacy outcome was time to treatment failure. MAIN RESULTS: Three months after the randomization of the last subject, the Data and Safety Monitoring Board determined that the primary research question had been answered and terminated the trial. The combination of montelukast and salmeterol was inferior to the combination of beclomethasone and salmeterol as judged by protection against asthma treatment failures (p = 0.0008), lung function (26 L/min difference in a.m. peak expiratory flow rate, p = 0.011), asthma control score (0.22 difference in Asthma Control Questionnaire score, p = 0.038), and markers of inflammation and airway reactivity. CONCLUSIONS:Patients with moderate asthma similar to those we studied should not substitute the combination of an LTRA and an LABA for the combination of inhaled corticosteroid and an LABA.
Authors: P M O'Byrne; P J Barnes; R Rodriguez-Roisin; E Runnerstrom; T Sandstrom; K Svensson; A Tattersfield Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: Graeme P Currie; Daniel K C Lee; Kay Haggart; Caroline E Bates; Brian J Lipworth Journal: Am J Respir Crit Care Med Date: 2002-11-27 Impact factor: 21.405
Authors: Elliot Israel; Paul S Chervinsky; Bruce Friedman; Julius Van Bavel; Carol S Skalky; Asma F Ghannam; Steven R Bird; Jonathan M Edelman Journal: J Allergy Clin Immunol Date: 2002-12 Impact factor: 10.793
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: S C Lazarus; H A Boushey; J V Fahy; V M Chinchilli; R F Lemanske; C A Sorkness; M Kraft; J E Fish; S P Peters; T Craig; J M Drazen; J G Ford; E Israel; R J Martin; E A Mauger; S A Nachman; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: Michael E Wechsler; Mario Castro; Erik Lehman; Vernon M Chinchilli; E Rand Sutherland; Loren Denlinger; Stephen C Lazarus; Stephen P Peters; Elliot Israel Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: Ryan M Dunn; Erik Lehman; Vernon M Chinchilli; Richard J Martin; Homer A Boushey; Elliot Israel; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira L Lugogo; Stephen P Peters; Christine A Sorkness; Stanley Szefler; Michael E Wechsler Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Kelly Wong McGrath; Nikolina Icitovic; Homer A Boushey; Stephen C Lazarus; E Rand Sutherland; Vernon M Chinchilli; John V Fahy Journal: Am J Respir Crit Care Med Date: 2012-01-20 Impact factor: 21.405
Authors: Anne Fuhlbrigge; David Peden; Andrea J Apter; Homer A Boushey; Carlos A Camargo; James Gern; Peter W Heymann; Fernando D Martinez; David Mauger; William G Teague; Carol Blaisdell Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Sharmilee M Nyenhuis; Jerry A Krishnan; Alalia Berry; William J Calhoun; Vernon M Chinchilli; Linda Engle; Nicole Grossman; Fernando Holguin; Elliot Israel; Rick A Kittles; Monica Kraft; Stephen C Lazarus; Erik B Lehman; David T Mauger; James N Moy; Stephen P Peters; Wanda Phipatanakul; Lewis J Smith; Kaharu Sumino; Stanley J Szefler; Michael E Wechsler; Sally Wenzel; Steven R White; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2017-01-06 Impact factor: 10.793